HK1129063A1 - Tumor-targeted nanodelivery systems to improve early mri detection of cancer - Google Patents

Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Info

Publication number
HK1129063A1
HK1129063A1 HK09106582.2A HK09106582A HK1129063A1 HK 1129063 A1 HK1129063 A1 HK 1129063A1 HK 09106582 A HK09106582 A HK 09106582A HK 1129063 A1 HK1129063 A1 HK 1129063A1
Authority
HK
Hong Kong
Prior art keywords
tumor
cancer
improve early
mri detection
targeted
Prior art date
Application number
HK09106582.2A
Inventor
Esther H Chang
Kathleen F Pirollo
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of HK1129063A1 publication Critical patent/HK1129063A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09106582.2A 2005-10-20 2009-07-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer HK1129063A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72830305P 2005-10-20 2005-10-20
PCT/US2006/041139 WO2007047981A2 (en) 2005-10-20 2006-10-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Publications (1)

Publication Number Publication Date
HK1129063A1 true HK1129063A1 (en) 2009-11-20

Family

ID=37963345

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09106582.2A HK1129063A1 (en) 2005-10-20 2009-07-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Country Status (8)

Country Link
JP (1) JP5478886B2 (en)
KR (1) KR20080064169A (en)
CN (1) CN101351225B (en)
AU (1) AU2006304790B2 (en)
CA (1) CA2638899C (en)
HK (1) HK1129063A1 (en)
IL (1) IL190773A (en)
WO (1) WO2007047981A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801344A (en) * 2007-07-09 2010-08-11 乔治敦大学 Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
CA3039251C (en) 2008-11-10 2024-01-09 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
CN102078624B (en) * 2010-12-23 2012-07-25 华东理工大学 Efficient Gd-loaded liposome preparation and preparation method thereof
WO2013031619A1 (en) * 2011-08-26 2013-03-07 学校法人藤田学園 Image-based tumor diagnosis agent containing anti-human transferrin receptor antibody
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2806896C (en) * 2012-09-19 2021-06-15 Georgetown University Targeted liposomes prepared by ethanol injection
KR20150131263A (en) * 2013-03-14 2015-11-24 조지타운 유니버시티 Treatment for exposure to nerve agent
EP3790533A1 (en) * 2018-05-08 2021-03-17 University of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3902794B2 (en) * 1997-03-07 2007-04-11 マックス−デルブルック−セントラム フュア モレクラーレ メディシン Specific magnetic material, its production method and use
ATE511543T1 (en) * 1999-02-22 2011-06-15 Univ Georgetown IMMUNOLIPOSOMES WITH A TARGETING ANTIBODY FRAGMENT FOR SYSTEMIC GENE ADMINISTRATION
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
WO2001082899A2 (en) * 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2003084386A2 (en) * 2002-04-03 2003-10-16 See Jackie R Methods for ultrasonic imaging and treating diseased tissues
US20040241088A1 (en) * 2003-01-28 2004-12-02 Georgetown University Method for evaluating the efficacy of certain cancer treatments
CN103251562B (en) * 2003-06-04 2016-04-27 乔治敦大学 The stability of flexible liposomes complex and the method for storage life
EP1648299A4 (en) * 2003-07-09 2008-10-22 California Pacific Med Center Remote detection of substance delivery to cells
JP2005170807A (en) * 2003-12-09 2005-06-30 Fuji Photo Film Co Ltd Liposome containing antibody

Also Published As

Publication number Publication date
CN101351225B (en) 2013-09-25
IL190773A0 (en) 2008-11-03
WO2007047981A2 (en) 2007-04-26
CN101351225A (en) 2009-01-21
KR20080064169A (en) 2008-07-08
WO2007047981A3 (en) 2007-10-25
JP5478886B2 (en) 2014-04-23
AU2006304790B2 (en) 2013-06-27
CA2638899A1 (en) 2007-04-26
CA2638899C (en) 2016-01-05
AU2006304790A1 (en) 2007-04-26
JP2009512712A (en) 2009-03-26
IL190773A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
HK1129063A1 (en) Tumor-targeted nanodelivery systems to improve early mri detection of cancer
GB0600682D0 (en) Improvements to doppler radar systems
EP2032594A4 (en) Glycyrrhetinic acid derivatives
PL2210246T3 (en) Proximity detection system
IL198062A0 (en) Improvements relating to the detection of patterns
ZA201001878B (en) Improved detection of mage-a-expression
IL176240A0 (en) Methods and systems using relative sensing to locate targets
SI1858929T1 (en) Diagnosis of prostate cancer
EP2147298A4 (en) Detection of cancer markers
IL198976A0 (en) Companion diagnostic assays for cancer therapy
EP2114432A4 (en) Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35
GB0820309D0 (en) Detection of cancer
EP2119018A4 (en) Techniques to deterministically reduce signal interference
GB0525541D0 (en) Detection of antibodies
HK1133161A1 (en) Piece of luggage
EP2212874A4 (en) Tracker and localizer of semi-trailers
HK1110655A1 (en) Diagnostic signal processor
GB0820899D0 (en) Early detection of sepsis
EP1856645A4 (en) Targets for detection of ischemia
ZA200710929B (en) Detection of hepatotoxic cyanobacteria
GB0709044D0 (en) Signal detection
GB0515325D0 (en) Improvements relating to the detection of lower limb disease
GB2444777B (en) Detection of radiation
GB0604231D0 (en) Cancer detection system
IL190949A0 (en) Jn vivo detection of apoptosis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171020